Ficd loss rescues motor impairments and reverses oligodendrocyte maturation deficits in a mouse model of spinocerebellar ataxia type 3
Preprint
Abstract
Spinocerebellar ataxia type 3 (SCA3) is an inherited, fatal neurodegenerative disease caused by a pathological CAG repeat expansion in the ATXN3 gene, resulting in the selective degeneration of vulnerable neuronal populations. Recent work has identified impairments in oligodendrocyte maturation as a novel and robust feature of SCA3 pathogenesis. Oligodendrocytes synthesize myelin structural components through the endoplasmic reticulum (ER), rendering this organelle essential for white matter integrity. Despite this, the role of ER function in SCA3 remains unclear. In this study, we show that loss of FICD-mediated AMPylation, a post-translational modification regulating the ER-resident HSP70 chaperone, BiP, rescues motor impairments in a transgenic SCA3 mouse model. Ficd -/- SCA3 mice exhibit significantly reduced levels of nuclear ATXN3 in vulnerable brain regions, while Ficd +/+ littermates show an increased burden of AMPylated BiP in the spinal cord, identifying aberrant AMPylation as a novel contributor of SCA3 pathology. Using unbiased proteomics, we demonstrate that Ficd deletion mitigates the pathological decrease in myelin structural proteins and oligodendrocyte maturation factors, restoring levels of mature, myelinating oligodendrocytes. In parallel, we show that Ficd activates SREBP2-dependent cholesterol biosynthesis to support myelination. Taken as a whole, these findings posit ER homeostasis as a critical driver of oligodendrocyte pathology and identify FICD as a novel target for alleviating non-neuronal toxicity in SCA3.Keywords
Funding Information
- National Institutes of Health (T32GM007315-43)
- National Institutes of Health (F31NS127485)
- National Institutes of Health (R35GM142561)
- National Institutes of Health (R35NS122302)
- National Institutes of Health (SBIR-R44NS127711-01)
- Cayman Chemical
This publication has 110 references indexed in Scilit:
- Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic TargetsMolecular Neurobiology, 2025
- RefFinder: a web-based tool for comprehensively analyzing and identifying reference genesFunctional & Integrative Genomics, 2023
- Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3Annals of Neurology, 2022
- A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in OligodendrocytesMolecular Neurobiology, 2021
- Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3Movement Disorders, 2021
- In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3Movement Disorders, 2020
- Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxiaActa Neuropathologica, 2019
- Survival and severity in dominant cerebellar ataxiasAnnals of Clinical and Translational Neurology, 2015
- White matter damage is related to ataxia severity in SCA3Journal of Neurology, 2013
- Machado‐Joseph disease gene product is a cytoplasmic protein widely expressed in brainAnnals of Neurology, 1997